ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Evotec and Bristol Myers Squibb are deepening their partnership on molecular glue degraders. Molecular glues are the next generation of targeted protein degraders, small molecules that lead a disease-causing protein to bind to an E3 ubiquitin ligase. This binding causes the protein to be degraded by cellular machinery. The companies will extend their partnership, started in 2018, by 8 years. Evotec will receive $200 million and milestone payments that could amount to $5 billion.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter